GSTM, GSTT and p53 polymorphisms as modifiers of clinical outcome in colorectal cancer

Anticancer Research

Volumn 28, Issue 3 B, 2008, Pages 1917-1922

  Csejtei, Andras ^a   Tibold, Antax ^b   Varga, Zsuzsa ^c   Koltai, Katalin ^b   Ember, Agoston ^b   Orsos, Zsuzsa ^b   Feher, Gergely ^b   Horvath, Ors Peter ^b   Ember, Istvan ^b   Kiss, Istvan ^b  

^a Markusovszky Teaching Hospital   (Hungary)

^b UNIVERSITY OF PÉCS   (Hungary)

^c Baranya County Hospital   (Hungary)

Author keywords

Colorectal cancer; Dukes' stage; GSTM1; GSTT1; p53; Polymorphism; Survival

Indexed keywords

DNA; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE T1; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COLORECTAL CANCER; DNA SEQUENCE; FEMALE; GENETIC POLYMORPHISM; HUMAN; HUMAN TISSUE; HUNGARY; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; ALLELES; COLORECTAL NEOPLASMS; FEMALE; GENES, P53; GLUTATHIONE TRANSFERASE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; POLYMORPHISM, GENETIC; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 45949112212     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Fuszek P, Horvath HC, Speer G, Papp J, Haller P, Fischer S, Halasz J, Jaray B, Szekely E, Schaff Z, Papp A, Bursics A, Harsanyi L, Lukovich P, Kupcsulik P, Hitre E and Lakatos PL: Location and age at onset of colorectal cancer in Hungarian patients between 1993-2004. The high number of advanced cases supports the need for a colorectal cancer screening program in Hungary. Anticancer Res 26: 527-532, 2006.
2. Parkin DM: Global cancer statistics in the year 2000. Lancet Oncol 2: 533-543, 2001.
3. Ottó S and Kásler M: Trends in cancer mortality and morbidity in Hungarian and international statistics. Characteristics and potential outcome of public health screening programs. (Article in Hungarian) Magy Onkol 49: 99-101, 103-107, 2005.
4. Mannervik B, Alin P, Guthenberg C, Jensson H, Tahir MK, Warholm M and Jörnvall H: Identification of three classes of cytosolic glutathione transferase common to several mammalian species: correlation between structural data and enzymatic properties. Proc Natl Acad Sci USA 82: 7202-7206, 1985.
5. Lizard-Nacol S, Coudert B, Colosetti P, Riedinger JM, Fargeot P and Brunet-Lecornte P: Glutathione-S-transferase M1 null genotype: lack of association with tumour characteristics and survival in advanced breast cancer. Breast Cancer Res 1: 81-87, 1999.
6. Pearson WR, Vorachek WR, Xu SJ, Berger R, Hart I, Vannais D and Patterson D: Identification of class-mu glutathione transferase genes GSTM1-GSTM5 on human chromosomelpl3. Am J Hum Genet 53: 220-233, 1993.
7. null genotypes of the glutathione-S-transferase gene are risk factor for CAD independent of smoking. BMC Med Genet 7: 38, 2006.
8. Gulick AM and Fahl WE: Forced evolution of glutathione-S-transferase to create a more efficient drug detoxification enzyme. Proc Natl Acad Sci USA 92: 8140-8144, 1995.
9. Seidegard J and Ekström G: The role of human glutathione-S- transferases and epoxide hydrolases in the metabolism of xenobiotics. Environ Health Perspect 105: 791-799, 1997.
10. Ketterer B, Harris JM, Talaska G, Meyer DJ, Pemble SE, Taylor JB, Lang NP and Kadlubar FF: The human glutathione-S-transferase supergene family, its polymorphism, and its effects on susceptibility to lung cancer. Environ Health Perspect 98: 87-94, 1992.
11. Hein DW, Tardon A, Serra C, Carrato A, Garcia-Closas R, Lloreta J, Castano-Vinyals G, Yeager M, Welch R, Chanock S, Chatterjee N, Wacholder S, Samanic C, Tora M, Fernandez F, Real FX and Rothman N: NAT2 slow acetylation, GSTMI null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet 366: 649-659, 2005.
12. Dumont P, Leu JI, Delia Pietra AC 3rd, George DL and Murphy M: The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33: 357-365, 2003.
13. Schneider-Stock R, Mawrin C, Motsch C, Boltze C, Peters B, Hartig R, Buhtz P, Giers A, Rohrbeck A, Freigang B and Roessner A: Retention of the Arginine Allele in Codon 72 of the p53 Gene Correlates with Poor Apoptosis in Head and Neck Cancer. Am J Pathol 164: 1233-1241, 2004.
14. Weston A and Godbold JH: Polymorphisms of H-ras-1 and p53 in breast cancer and lung cancer: a meta-analysis. Environ Health Perspect 105(Suppl 4): 919-926, 1997.
15. Dukes CE: The classification of cancer of the rectum. J Pathol Bact 35: 323-332, 1932.
16. Zhu ZZ, Wang AZ, Jia HR, Jin XX, He XL, Hou LF and Zhu G: Association of the TP53 codon 72 polymorphism with colorectal cancer in a Chinese Population. Jpn J Clin Oncol 37: 385-390, 2007.
17. Koushik A, Tranah GJ, Ma J, Stampfer MJ, Sesso HD, Fuchs CS, Giovannucci EL and Hunter DJ: p53 Arg72Pro polymorphism and risk of colorectal adenoma and cancer. Int J Cancer 119: 1863-1868, 2006.
18. Pérez LO, Abba MC, Dulout FN and Golijow CD: Evaluation of p53 codon 72 polymorphism in adenocarcinomas of the colon and rectum in La Plata, Argentina. World J Gastroenterol 12: 1426-1429, 2006.
19. Sachse C, Smith G, Wilkie MJ, Barrett JH, Waxman R, Sullivan F, Forman D, Bishop DT, Wolf CR; Colorectal Cancer Study Group: A pharmacogenetic study to investigate the role of dietary carcinogens in the etiology of colorectal cancer. Carcinogenesis 23: 1839-1849, 2002.
20. Chunhong Fan, Mingjuan Jin, Kun Chen, Yongjing Zhang, Shuangshuang Zhang and Bing Liu: Case-only study of interactions between metabolic enzymes and smoking in colorectal cancer. BMC Cancer 7: 115, 2007.
21. Loktionov A, Watson MA, Gunter M, Stebbings WS, Speakman CT and Bingham SA: Glutathione-S-transferase gene polymorphisms in colorectal cancer patients: interaction between GSTM1 and GSTM3 allele variants as a risk-modulating factor. Carcinogenesis 22: 1053-1060, 2001.